{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:20:38Z","timestamp":1785270038979,"version":"3.55.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T00:00:00Z","timestamp":1620345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.vhri.2021.04.003","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T18:25:02Z","timestamp":1637173502000},"page":"54-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan"],"prefix":"10.1016","volume":"28","author":[{"given":"Kosuke","family":"Morimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Moriwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Kaneyasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojiro","family":"Shimozuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vhri.2021.04.003_bib2","series-title":"Clinical Practice Guidelines for Pancreatic Cancer 2019","year":"2019"},{"issue":"10","key":"10.1016\/j.vhri.2021.04.003_bib3","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1007\/s12325-018-0784-z","article-title":"Comparative effectiveness of nab-paclitaxel plus gemcitabine vs FOLFIRINOX in metastatic pancreatic cancer: a retrospective Nationwide chart review in the United States","volume":"35","author":"Kim","year":"2018","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.vhri.2021.04.003_bib4","doi-asserted-by":"crossref","first-page":"566","DOI":"10.21037\/jgo.2017.02.02","article-title":"Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer","volume":"8","author":"Muranaka","year":"2017","journal-title":"J\u00a0Gastrointest Oncol"},{"issue":"18","key":"10.1016\/j.vhri.2021.04.003_bib5","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.vhri.2021.04.003_bib7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/14737167.2018.1464394","article-title":"An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel)\u00a0+ gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study","volume":"18","author":"Lazzaro","year":"2018","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"4","key":"10.1016\/j.vhri.2021.04.003_bib8","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1586\/14737167.2015.1047349","article-title":"Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study","volume":"15","author":"Carrato","year":"2015","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"8","key":"10.1016\/j.vhri.2021.04.003_bib9","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/bjc.2015.65","article-title":"Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreatic cancer","volume":"112","author":"Gharaibeh","year":"2015","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.vhri.2021.04.003_bib10","first-page":"345","article-title":"Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreatic cancer","volume":"20","author":"Gharaibeh","year":"2017","journal-title":"J\u00a0Med Econ"},{"issue":"1","key":"10.1016\/j.vhri.2021.04.003_bib11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3892\/mco.2017.1278","article-title":"Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer","volume":"7","author":"Kurimoto","year":"2017","journal-title":"Mol Clin Oncol"},{"issue":"1","key":"10.1016\/j.vhri.2021.04.003_bib12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jval.2019.10.005","article-title":"Formal implementation of cost-effectiveness evaluations in Japan: a unique health technology assessment system","volume":"23","author":"Hasegawa","year":"2020","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.vhri.2021.04.003_bib13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40273-013-0123-9","article-title":"Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial","volume":"32","author":"Diaby","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vhri.2021.04.003_bib15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"10.1016\/j.vhri.2021.04.003_bib18","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials\u2013extrapolation with patient-level data: inconsistencies, limitations and a practical guide","volume":"33","author":"Latimer","year":"2013","journal-title":"Med Decis Making"},{"issue":"2","key":"10.1016\/j.vhri.2021.04.003_bib19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jpainsymman.2011.09.001","article-title":"Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized Phase 3 trial of the Cancer and Leukemia Group B (CALGB 80303)","volume":"43","author":"Romanus","year":"2012","journal-title":"J\u00a0Pain Symptom Manag"},{"issue":"1","key":"10.1016\/j.vhri.2021.04.003_bib20","first-page":"1","article-title":"Assessment of medical information databases to estimate patient numbers","volume":"19","author":"Shimizu","year":"2014","journal-title":"Jpn J Pharmacoepidemiol"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109921000431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109921000431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:12:51Z","timestamp":1761941571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109921000431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":15,"alternative-id":["S2212109921000431"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2021.04.003","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2021.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 ISPOR--The professional society for health economics and outcomes research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}